Skandinaviska Enskilda Banken AB publ grew its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) by 55.8% during the second quarter, Holdings Channel.com reports. The firm owned 26,195 shares of the company’s stock after acquiring an additional 9,385 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Kyverna Therapeutics were worth $196,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in KYTX. Federated Hermes Inc. bought a new position in shares of Kyverna Therapeutics in the second quarter valued at about $120,000. Rhumbline Advisers bought a new position in shares of Kyverna Therapeutics in the second quarter worth about $150,000. DekaBank Deutsche Girozentrale bought a new position in shares of Kyverna Therapeutics in the first quarter worth about $181,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Kyverna Therapeutics during the first quarter worth approximately $313,000. Finally, Sofinnova Investments Inc. grew its stake in shares of Kyverna Therapeutics by 378.5% during the second quarter. Sofinnova Investments Inc. now owns 47,850 shares of the company’s stock valued at $359,000 after purchasing an additional 37,850 shares during the last quarter. Institutional investors own 18.08% of the company’s stock.
Kyverna Therapeutics Stock Down 4.4 %
KYTX opened at $5.59 on Wednesday. The company has a fifty day moving average price of $7.71 and a two-hundred day moving average price of $13.19. Kyverna Therapeutics, Inc. has a 52 week low of $5.53 and a 52 week high of $35.06.
Wall Street Analyst Weigh In
Several research analysts have issued reports on KYTX shares. JPMorgan Chase & Co. reduced their price objective on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. HC Wainwright reaffirmed a “neutral” rating and set a $7.00 price target on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.40.
Read Our Latest Stock Report on Kyverna Therapeutics
Kyverna Therapeutics Company Profile
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
See Also
- Five stocks we like better than Kyverna Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- How to Use the MarketBeat Stock Screener
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Stock Market Upgrades: What Are They?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report).
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.